Drug updated on 12/11/2024
| Dosage Form | Tablet (oral; valsartan/HCTZ: 80 mg /12.5 mg, 160 mg /12.5 mg, 160 mg /25 mg, 320 mg /12.5 mg, 320 mg /25 mg) |
| Drug Class | Angiotensin II receptor blockers and thiazide diuretics |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of hypertension, to lower blood pressure in patients not adequately controlled with monotherapy
- Indicated for the treatment of hypertension as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals.
Latest News
Summary
- This summary is based on the review of three systematic review(s)/meta-analysis(es). [1-3]
- The combination of valsartan 320 mg with amlodipine 10 mg demonstrated significant antihypertensive effects in general hypertensive patients without major adverse effects, while valsartan combined with hydrochlorothiazide 25 mg did not result in additional blood pressure reduction compared to lower doses of valsartan.
- Fixed-dose combinations of angiotensin receptor blocker (ARB) with a lower dose of hydrochlorothiazide (12.5 mg) were effective for hypertension management and presented a safer profile regarding dyskalemia, suggesting they may be preferable in hypertensive populations at risk for electrolyte imbalances.
- Single-pill combinations, such as amlodipine/valsartan, showed efficacy in patients with uncontrolled essential hypertension, with ARB/calcium channel blocker (CCB) combinations outperforming monotherapy in reducing both systolic and diastolic blood pressure.
- Common adverse effects associated with valsartan-based therapies included dizziness, headache, nasopharyngitis, asthenia, and urticaria; specifically, valsartan 320 mg combined with amlodipine 10 mg did not result in significant adverse effects, and the combination with hydrochlorothiazide 25 mg did not increase the incidence of adverse effects compared to lower doses of valsartan.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Diovan HCT (valsartan and hydrochlorothiazide) Prescribing Information. | 2020 | Novartis Pharmaceuticals Corporation, East Hanover, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Two-Drug Combinations Therapy of Different Doses of Valsartan Existing Diverse Significance for Hypertensive Patients | 2023 | Reviews in Cardiovascular Medicine |
| Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis. | 2023 | Clinical Cardiology |
| Dyskalemia risk associated with fixed-dose anti-hypertensive medication combinations | 2022 | Journal of Human Hypertension |